[Bortezomib-induced peripheral neuropathy in multiple myeloma patients].
Li Shao(First Affiliated Hospital Zhejiang University), Jie Jin(Beijing Institute of Technology), Wenyuan Mai(First Affiliated Hospital Zhejiang University), Hongyan Tong(First Affiliated Hospital Zhejiang University), Liping Mao(First Affiliated Hospital Zhejiang University), Shasha Wang(Chinese PLA General Hospital), Wenbin Qian(Ministry of Education of the People's Republic of China), Juying Wei(First Affiliated Hospital Zhejiang University), Jiejing Qian(First Affiliated Hospital Zhejiang University), Haitao Meng(First Affiliated Hospital Zhejiang University), Wenjuan Yu(Zhejiang Cancer Hospital)
PubMed
October 1, 2015
Cited by 3
Related Papers
Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial
|The Lancet Haematology|2019|248
Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma
|Cancer Cell|2020|238
Synthesis of Hemoglobin Conjugated Polymeric Micelle: A ZnPc Carrier with Oxygen Self-Compensating Ability for Photodynamic Therapy
|Biomacromolecules|2015|136
Induction of USP25 by viral infection promotes innate antiviral responses by mediating the stabilization of TRAF3 and TRAF6
|Proceedings of the National Academy of Sciences|2015|132
Systemic Lupus Erythematous and Malignancy Risk: A Meta-Analysis
|PLoS ONE|2015|115